Inhibition of adipogenesis

• US 20010046966A1
• Filed: 02/20/2001
• Published: 11/29/2001
• Est. Priority Date: 02/17/2000
• Status: Abandoned Application

• Current Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Original Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Inventors: Tong, Qiang, Hotamisligil, Gokhan S.
• Application Number:
  US09/788,857
• Publication Number:
  US 20010046966A1
• Time in Patent Office: Days
• US Class Current: 514/44
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The invention features compositions and methods for inhibiting adipogenesis by increasing GATA-2 or GATA-3 expression. Also included are methods of treating lipdystrophy by decreasing GATA-2 or GATA-3 expression.

Claims

1. A method of inhibiting adipogenesis, comprising contacting an adipocyte or adipocyte precursor with a compound that increases GATA-2 or GATA-3 expression.

2. The method of

claim 1

, wherein said compound increases GATA-2 expression.

3. The method of

claim 1

, wherein said compound increases GATA-3 expression.

4. The method of

claim 1

, wherein said compound is a nucleic acid molecule encoding a GATA-2 polypeptide.

5. The method of

claim 1

, wherein said compound is an inducer of GATA-2 expression.

6. The method of

claim 1

, wherein said compound is an inducer of GATA-3 expression.

7. The method of

claim 5

or

6

, wherein said compound binds to a cis-acting regulatory region of a GATA-2 or GATA-3 gene and augments transcription of a GATA-2 or GATA-3 gene.

8. A method of inhibiting adipogenesis, comprising contacting an adipocyte or adipocyte precursor with a GATA-2 polypeptide.

10. The method of

claim 8

or

9

, wherein said polypeptide comprises a zinc finger domain.

9. A method of inhibiting adipogenesis, comprising contacting an adipocyte or adipocyte precursor with a GATA-3 polypeptide.

11. A method of treating obesity, comprising administering to a mammal a compound which increases expression of GATA-2 or GATA-3.

12. A method of treating obesity, comprising administering to a mammal a polypeptide selected from the group consisting of a GATA-2 polypeptide or a GATA-3 polypeptide.

13. The method of

claim 12

, wherein said polypeptide is a GATA-2 polypeptide.

14. The method of

claim 12

, wherein said polypeptide is a GATA-3 polypeptide.

15. A method of treating lipodystrophy in a mammal comprising administering to said mammal a compound which inhibits expression of GATA-2 or GATA-3.

16. The method of

claim 15

, wherein said compound inhibits expression of GATA-2.

17. The method of

claim 15

, wherein said compound inhibits expression of GATA-3.